A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
B-cell Acute Lymphoblastic Leukemia
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2/3
- Patients
- 340 (planned)
- Started
- May 18, 2026
- Main results expected
- Oct 18, 2033
- Fully finished
- Oct 18, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants with Complete Remission (CR) in Study Part 1 and Part 2
Measured over: 3 treatment cycles (up to approximately 126 days; each cycle is up to 42 days; cycle lengths vary between cycle and arm)
Percentage of Participants Who Experience an Adverse Event (AE) in Study Part 1
Measured over: 3 treatment cycles (up to approximately 126 days; each cycle is up to 42 days; cycle lengths vary between cycle and arm)
Percentage of Participants Who Discontinue Study Intervention Due to an AE in Study Part 1
Measured over: 3 treatment cycles (up to approximately 126 days; each cycle is up to 42 days; cycle lengths vary between cycle and arm)
Overall Survival (OS) in Study Part 2
Measured over: Up to approximately 7 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07570173 · record last updated 2026-10-30 · checked 2026-11-09 15:47 UTC